Enhanced Surveillance On Sero-Prevalence Of Sars-Cov-2 in the General Population

The study is the first serosurvey conducted from a planned series of seroprevalence studies for COVID-19 in Nepal. Research has found an estimated national seroprevalence was 14.4% (95% CI, 11.8-17.0). The actual infection prevalence is far greater than the observed case prevalence observed through routine surveillance systems (English).